NDATOPICALOINTMENT
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
15
Data completeness
6/8 — Strong
EUCRISA (crisaborole) by R-Pharm US is phosphodiesterase 4 inhibitors [moa]. First approved in 2016.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EUCRISA (crisaborole) is a topical phosphodiesterase 4 inhibitor ointment approved in December 2016 for atopic dermatitis. It works by inhibiting PDE-4, reducing inflammatory cytokine production in the skin. This is the first and only non-steroidal, non-calcineurin inhibitor topical treatment in its class.
$0.01BPart D
Peak4.1 years to LOEProduct is at peak lifecycle with $10M in Part D spending (2023); mature brand team focused on maintaining market position against rising competitive pressure (8/10).
Mechanism of Action
Phosphodiesterase 4 Inhibitors
Pharmacologic Class:
Phosphodiesterase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
Started Sep 2022
32 enrolled
Vitiligo
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
Started Sep 2020
40 enrolled
Atopic Dermatitis
Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis
Started Jul 2020
391 enrolled
Atopic Dermatitis
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Started Jun 2020
66 enrolled
Stasis Dermatitis
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
Started Feb 2020
150 enrolled
Atopic Dermatitis
Worked on EUCRISA at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.